Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459688 | 0.86 | FAAH (0.51) | FAAHGPR119 | |
| SCHEMBL11956851 | 0.86 | FAAH (0.47) | FAAHGPR119 | |
| SCHEMBL8354737 | 0.84 | FAAH (0.46) | FAAHGPR119GRIN2B | |
| SCHEMBL7988738 | 0.84 | FAAH (0.46) | FAAHGPR119GRIN2B | |
| SCHEMBL14895593 | 0.83 | GPR119 (0.45) | FAAHGPR119GRIN2B | |
| SCHEMBL1575630 | 0.83 | FAAH (0.55) | FAAHGPR119 | |
| SCHEMBL14116719 | 0.83 | FAAH (0.51) | FAAHGPR119 | |
| SCHEMBL1721269 | 0.83 | FAAH (0.45) | FAAHGPR119GRIN2B | |
| SCHEMBL3182420 | 0.82 | GPR119 (0.55) | FAAHGPR119 | |
| SCHEMBL388068 | 0.81 | GPR119 (0.43) | FAAHGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258156-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-09-04 | — | — | US | disclosed |
| US-8258156-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-09-04 | — | — | US | disclosed |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-8153635-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-8153635-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009038974-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | FAAH 2885/4885GPR119 1/4885GRIN2B 1748/4885 |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | FAAH 814/4885GPR119 1/4885GRIN2B 440/4885 |
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | FAAH 953/4885GPR119 1/4885GRIN2B 1017/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | FAAH 744/4885GPR119 1/4885GRIN2B 275/4885 |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | FAAH 744/4885GPR119 1/4885GRIN2B 275/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | FAAH 2885/4885GPR119 1/4885GRIN2B 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.